6,7-dimethoxy-2-[4-(oxolane-2-carbonyl)piperazin-1-yl]quinazolin-4-amine

• ChemBase编号: 1033
• 分子式: C19H25N5O4
• 平均质量: 387.4329
• 单一同位素质量: 387.19065431
• SMILES: O1C(CCC1)C(=O)N1CCN(CC1)c1nc2c(c(n1)N)cc(OC)c(OC)c2
• Canonical SMILES: COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)C1CCCO1
• InChI: InChI=1S/C19H25N5O4/c1-26-15-10-12-13(11-16(15)27-2)21-19(22-17(12)20)24-7-5-23(6-8-24)18(25)14-4-3-9-28-14/h10-11,14H,3-9H2,1-2H3,(H2,20,21,22)
• InChIKey: VCKUSRYTPJJLNI-UHFFFAOYSA-N

名称和登记号

名称

• IUPAC标准名: 6,7-dimethoxy-2-[4-(oxolane-2-carbonyl)piperazin-1-yl]quinazolin-4-amine
• IUPAC传统名: 6,7-dimethoxy-2-[4-(oxolane-2-carbonyl)piperazin-1-yl]quinazolin-4-amine; terazosin
• 商标名: Blavin; Flumarc; Fosfomic; Heitrin; Hytracin; Hytrin; Hytrinex; Itrin; Urodie; Vasomet; Vicard
• 别名: Terazosin HCl; Terazosin hydrochloride; Terazosina [INN-Spanish]; Terazosine; Terazosine [INN-French]; Terazosinum [INN-Latin]; Trazosin HCl; Abbott 45975; Terazosin; 6,7-dimethoxy-2-[4-(oxolane-2-carbonyl)piperazin-1-yl]quinazolin-4-amine

登记号

• CAS号: 63590-64-7
• MDL号: MFCD00072144
• PubChem SID: 46509129; 160964496
• PubChem CID: 5401

理论计算性质

JChem

• Acid pKa: 19.929197
• 质子受体: 8
• 质子供体: 1
• LogD (pH = 5.5): -0.32373834
• LogD (pH = 7.4): 0.95433736
• Log P: 1.1797276
• 摩尔折射率: 105.1764 cm^3
• 极化性: 40.394585 Å^3
• 极化表面积: 103.04 Å^2
• 可自由旋转的化学键: 4
• 里宾斯基五规则: true

ALOGPS 2.1

• Log P: 1.12
• LOG S: -2.41
• 溶解度: 1.50e+00 g/l

分子性质

理化性质

• 溶解度: 29.7mg/mL
• 疏水性(logP): 1; 2.182

产品相关信息

• 纯度: 95%

详细说明

DrugBank - DB01162

• Drug Groups: approved
• Description: Terazosin is a selective alpha1-antagonist used for treatment of symptoms of benign prostatic hyperplasia (BPH). It also acts to lower blood pressure, so it is a drug of choice for men with hypertension and prostate enlargement. It works by blocking the action of adrenaline on smooth muscle of the bladder and the blood vessel walls.
• Indication: For the treatment of symptomatic BPH and mild to moderate hypertension.
• Pharmacology: Terazosin, classified as a quinazoline, is similar to doxazosin and prazosin. As an α-adrenergic blocking agent, terazosin is used to treat hypertension and BPH. Terazosin produces vasodilation and reduces peripheral resistance but in general has only a slight effect on cardiac output. The antihypertensive effect with chronic dosing is not usually accompanied by reflex tachycardia.
• Toxicity: LD₅₀=259.3mg/kg (IV in mice)
• Affected Organisms: Humans and other mammals
• Biotransformation: Hepatic. One of the four metabolites identified (piperazine derivative of terazosin) has antihypertensive activity.
• Absorption: Essentially completely absorbed in man (90% bioavailability).
• Half Life: 12 hours
• Protein Binding: 90-94%
• Elimination: Approximately 10% of an orally administered dose is excreted as parent drug in the urine and approximately 20% is excreted in the feces.
• References: Cushman WC, Ford CE, Cutler JA, Margolis KL, Davis BR, Grimm RH, Black HR, Hamilton BP, Holland J, Nwachuku C, Papademetriou V, Probstfield J, Wright JT Jr, Alderman MH, Weiss RJ, Piller L, Bettencourt J, Walsh SM: Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich). 2002 Nov-Dec;4(6):393-404. [Pubmed]
• External Links: Wikipedia; RxList; Drugs.com

参考文献

• Cushman WC, Ford CE, Cutler JA, Margolis KL, Davis BR, Grimm RH, Black HR, Hamilton BP, Holland J, Nwachuku C, Papademetriou V, Probstfield J, Wright JT Jr, Alderman MH, Weiss RJ, Piller L, Bettencourt J, Walsh SM: Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich). 2002 Nov-Dec;4(6):393-404. Pubmed